Literature DB >> 19259275

Thromboembolism in gastrointestinal cancers.

Eric D Tetzlaff1, Jonathan D Cheng, Jaffer A Ajani.   

Abstract

The link between thromboembolism and cancer has been recognized for over 100 years. Venous thromboembolism (VTE) is associated with considerable morbidity in patients with cancer, with emerging research also indicating a detrimental effect on survival. Investigations aimed at improving outcomes for patients with cancer have focused on the role of low molecular weight heparin in primary and secondary prevention of VTE and in improving patient survival. Important fundamental questions remain unanswered, however, and a significant line of research needs to be dedicated to investigating VTE in GI cancers. The effect of VTE on survival needs to be clarified, as does the role of anticoagulation in this patient population. Opportunities for additional research include investigating methods to identify patients at risk of developing VTE and developing new strategies and therapeutic interventions to reduce the morbidity and mortality associated with VTE. This review focuses on the current understanding of VTE related to gastrointestinal cancers and directions of interest in research specific to GI cancers and VTE.

Entities:  

Year:  2008        PMID: 19259275      PMCID: PMC2632566     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  55 in total

1.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Authors:  Manish A Shah; David Ilson; David P Kelsen
Journal:  J Clin Oncol       Date:  2005-03-28       Impact factor: 44.544

2.  Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group.

Authors:  B Lebeau; C Chastang; J M Brechot; F Capron; B Dautzenberg; C Delaisements; M Mornet; J Brun; J P Hurdebourcq; E Lemarie
Journal:  Cancer       Date:  1994-07-01       Impact factor: 6.860

Review 3.  The complex effects of heparins on cancer progression and metastasis in experimental studies.

Authors:  S M Smorenburg; C J Van Noorden
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

4.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

Authors:  Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

5.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

Review 7.  Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?

Authors:  Marc Carrier; Grégoire Le Gal; Philip S Wells; Dean Fergusson; Tim Ramsay; Marc A Rodger
Journal:  Ann Intern Med       Date:  2008-09-02       Impact factor: 25.391

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies.

Authors:  C Mao; D R Domenico; K Kim; D J Hanson; J M Howard
Journal:  Arch Surg       Date:  1995-02
View more
  4 in total

1.  Spontaneous free floating carotid artery thrombosis.

Authors:  Ruth Graham; Marek Blaszczynski
Journal:  BMJ Case Rep       Date:  2013-06-07

2.  Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy.

Authors:  Thura Win Htut; Kyaw Zin Thein; Donald Paul Quick; Thein Hlaing Oo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-09-16

3.  Similar Quality of Life and Safety in Patients Receiving Inpatient or Outpatient Chemotherapy: A Focus on Esophageal Squamous Cell Carcinoma.

Authors:  Yen-Hao Chen; Su-Wei Chen; Hung-I Lu; Chien-Ming Lo; Shau-Hsuan Li
Journal:  Healthcare (Basel)       Date:  2020-11-01

4.  Incidental Finding of Saddle Pulmonary Embolism on a CT Scan of the Abdomen and Pelvis in a Patient With Adenocarcinoma of the Colon.

Authors:  Seyed M Nahidi; Uzayr Ali; Leonidha Duka; Juan C Fuentes-Rosales; Utpal Bhatt
Journal:  Cureus       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.